вторник, 24 января 2017 г.

MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence

MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence


MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that the medical journal Neuropsychopharmacology has published a new article on MN-166 written by Dr. Lara Ray and colleagues at the University of California, Los Angeles. The article reports that MN-166 was associated with mood improvements on the stress- and alcohol-cue exposures, as well as reductions in overall craving, depression and anxiety for alcohol in subjects diagnosed with alcohol use disorder .



from Biotech News